Gemcitabine HCl Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2027

Published on : Mar-2020 | List of Tables : 92 | List of Figures : 91 | No. of Pages : 170 | Report Code : FACT4646MR |

Gemcitabine HCl Market Experiences Healthy 6.7% Growth Through 2027

Consistent R&D in the healthcare industry is offering material benefits to the society, thereby, substantially improving the average life expectancies and quality of living. In addition, the healthcare vertical is accelerating its shift towards a value-based structure that includes rethinking patient care delivery, cost-effectiveness, and customizing patient experience.

As per the World Health Organization (WHO), cancer causes about 16% of mortalities all over the world, with around 70% of them occurring in low- and middle-income economies (LME). In the US alone, nearly 90, 000 cancer cases are estimated to be diagnosed in 2020. This demanding situation is compelling governments all over the world to invest in healthcare system at scale, particularly in oncology research, in a bid to reach a larger patient base.

Against this backdrop, the global gemcitabine HCl market will grow at a healthy CAGR of 6.7% over 2020-2027. Among the end users, hospitals are expected to capture higher revenue share, while upsurge in oncology research projects in cancer centers are offering new revenue streams.

Preference for Generic Drugs to Remain Intact

Both, generic and branded drugs exhibit identical efficiency in cancer treatment, and contain the same active ingredient. However, generic drugs emerge as clear winner in terms of cost, as such, and this is garnering huge investments from stakeholders. Hospitals and cancer research centers are encountering supply shortage of generic injectable drugs in key therapeutic areas such as oncology, and cardiology, a potential opportunity for gemcitabine HCl market players.

Over a third of generic injectable products for cancer treatment are going off-patent by 2020, and the trend is likely to grow over the forecast period. Furthermore, Fact.MR finds that, the value creation of generic drugs will be around thrice that of the branded drugs.

gemcitabine  market 1

To get an exhaustive overview of the gemcitabine market, ask an analyst here

North America in Vanguard, APAC to Emerge as Fast-Growing Market  

Capturing around 40% of total gemcitabine HCl market stack, North America continues to engage shareholders over the time ahead. Being a hotbed for innovations in the healthcare sector, favorable reimbursement policies and notable resource allocation to improve healthcare infrastructure are key factors shaping market in the developed region.

Manufacturers are also turning their sights to Asia Pacific (APAC), where the gemcitabine HCl market is expected to flourish at a noteworthy CAGR of over 7%. In order to curb the expanding cancer patient pool, governments in countries – China, and India – are increasing their per capita healthcare spending. Furthermore, this study reveals that, the usage of gemcitabine HCl in APAC is likely to surge to about 1.6x through 2027.

Market Players Emphasize on Reformulation Strategies to Maintain Competitiveness

R&D projects in the gemcitabine HCl drug market in the recent past have been primarily focusing on advancements in treatment delivery and combination therapy. High unmet needs and limited efficacy of existing treatments in pancreatic cancer (mostly chemotherapies) have influenced market incumbents to explore better versions of branded gemcitabine agents.

For instance, NuCana Biomed’s Acelarin (NUC-1031), a reformulation of gemcitabine, is in late-stage clinical trials and has been engineered to overcome resistance mechanisms associated with the original drug. Sun Pharma has launched ready-to-infuse INFUGEM (gemcitabine in sodium chloride injection) in the U.S. INFUGEM - the first chemotherapy product that comes in a premixed formulation. The reformulation received approval by the U.S. Food and Drug Administration (FDA) in combination with other drugs for the treatment of breast, ovarian, non-small cell lung cancers, and as a single agent for the treatment of pancreatic cancer.

gemcitabine  market  2

Get the latest, cutting-edge market insights on the gemcitabine competition landscape by requesting for a report sample here

Gemcitabine HCl Market - Scope of the Report

The following study offers projection and assessment of the global gemcitabine HCl market along with the estimated data 2020 and forecast data up to 2027 in terms of value (US$ Mn) and volume (Kg), as per a Fact.MR report. The report provides key trends that are currently impacting growth of the global gemcitabine HCl market along with numerous macro-economic indicators. This recently published and insightful study on gemcitabine HCl puts emphasis on important dynamics, and their effect on the entire value chain from suppliers to end-users, which are likely to shape the future landscape of the global gemcitabine HCl market.  

The Fact.MR study incorporates an in-depth analysis of recent industry trends and opportunities for gemcitabine HCl manufacturers. It also consists of value chain analysis including, the key market participants. To facilitate users with a 360-degree view of the market, we have included a comprehensive competitive assessment about the leading players operating players in the market and strategic synopses. The dashboard included in the report offers a thorough comparison of gemcitabine HCl producers on aspects - product offerings, total revenue, and key tactics.

Gemcitabine HCl Market: In-Depth Analysis on Key Segments

Fact.MR has studied the gemcitabine HCl market with detailed segmentation on the basis of type, application, end users, and key regions.

Type

Application

End Users

Region

Branded

Pancreatic Cancer

Hospitals

North America

Generic

Breast Cancer

Cancer Centers

Europe

 

Ovarian Cancer

Others

Asia-Pacific

 

Non-small-cell lung carcinoma (NSCLC)

 

Latin America

 

Others

 

Middle East & Africa

“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.”

The Fact.MR study covers country-specific analysis on demand for gemcitabine HCl for each regional market in tandem with the market size valuation and projected price point analysis, price index, and impact of major regional and country-wise dynamics, which were gathered via quotes from several gemcitabine HCl manufacturers, experts, and suppliers. The study also provides Y-o-Y growth projections on every regional market covered. Further, future trends, growth opportunities, and other factors associated with the market have been elaborated in the study.

The report offers company-level market share assessment, which has been deduced based on the company’s yearly sales and segmental revenue in every target end-use sectors. The market has been projected on the basis of constant currency rates. The report also offer detailed competitive and company profiles of key participants running in the global gemcitabine HCl market. Some of the major competitors operating in the robot process automation market are Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Accord-UK Ltd., Pfizer, Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, Dr. Reddy’s Laboratories Ltd., Ingenus Pharmaceuticals, and others.

Gemcitabine HCl Market: Research Methodology

Numerous primary and secondary sources were referred to during the course of the report. The latter include Morningstar, Factiva, and Hoovers, and company yearly reports and publications. Comprehensive interviews have been organized by our analysts, and the intelligence and insights gathered have been utilized for authenticating the data collected via secondary research. The study also contains an elaboration of assumptions and acronyms used for research purposes. Information collected has been authenticated with the help of the triangulation method to provide compelling quantitative and qualitative insights into the gemcitabine HCl market.

A brief market perspective covered in the study explains the macro-economic aspects that influence the growth of the gemcitabine HCl market including, global GDP growth rate, various sectors growth rate such as healthcare, pharmaceutical, and others. This study serves as a genuine resource of intelligence on the gemcitabine HCl market, encouraging the readers to implement fact-based decisions on the future outlook of their businesses.

1. Preface 

    1.1. Report Scope and Market Segmentation

    1.2. Research Highlights

2. Assumptions and Research Methodology

    2.1. Assumptions and Acronyms Used

    2.2. Research Methodology

3. Executive Summary

    3.1. Global Gemcitabine HCL Market Analysis, by Region, 2020 and 2027

    3.2. Global Gemcitabine HCL Market: Market Snapshot

4. Market Overview

    4.1. Global Gemcitabine HCL Market Overview

    4.2. Global Gemcitabine HCL Market Key Industry Developments

5. Market Dynamics

    5.1. Drivers and Restraints Snapshot Analysis

    5.2. Drivers

    5.3. Restraints

    5.4. Opportunities

6. Key Insights

    6.1. Disease Prevalence & Incidence Rate globally with key countries

    6.2. Regulatory Scenario by Region/globally

    6.3. Pipeline Analysis

    6.4. Key Mergers & Acquisitions

    6.5. Pricing Analysis of Finished products

    6.6. Overview of Manufacturers

    6.7. Consumption of Gemcitabine HCl (Volume) per Region (2018)

    6.8. Prices by Key Manufacturers(USD/kg)

    6.9. Overview of Manufacturers

7. Global Gemcitabine HCL Market Analysis, by Type

    7.1. Introduction

    7.2. Key Insights

    7.3. Global Gemcitabine HCL Market Size and Forecast, by Type

        7.3.1. Branded

        7.3.2. Generic

    7.4. Global Gemcitabine HCL Market Analysis, by Type

    7.5. Global Gemcitabine HCL Market Attractiveness Analysis, by Type

8. Global Gemcitabine HCL Market Analysis, by Application

    8.1. Introduction

    8.2. Key Insights

    8.3. Global Gemcitabine HCL Market Size and Forecast, by Application

        8.3.1. Pancreatic Cancer

        8.3.2. Breast Cancer

        8.3.3. Ovarian Cancer

        8.3.4. Non-small-cell lung carcinoma (NSCLC)

        8.3.5. Other

    8.4. Global Gemcitabine HCL Market Analysis, by Application

    8.5. Global Gemcitabine HCL Market Attractiveness Analysis, by Application

9. Global Gemcitabine HCL Market Analysis, by End-user

    9.1. Introduction

    9.2. Key Insights

    9.3. Global Gemcitabine HCL Market Application and Forecast, by End-user

        9.3.1. Hospitals

        9.3.2. Cancer Centers

        9.3.3. Others

    9.4. Global Gemcitabine HCL Market Analysis, by End-user

    9.5. Global Gemcitabine HCL Market Attractiveness Analysis, by End-user

10. Global Gemcitabine HCL Market Analysis, by Region

    10.1. Introduction

    10.2. Key Insights

    10.3. Global Gemcitabine HCL Market Size and Forecast , by Region, 2014–2027

        10.3.1. North America

        10.3.2. Europe

        10.3.3. Asia Pacific

        10.3.4. Latin America

        10.3.5. Middle East & Africa

    10.4. Global Gemcitabine HCL Market Analysis, by Region

    10.5. Global Gemcitabine HCL Market Attractiveness Analysis, by Region

11. North America Gemcitabine HCL Market Analysis

    11.1. North America Gemcitabine HCL Market Key Findings

    11.2. North America Gemcitabine HCL Market Overview

    11.3. North America Gemcitabine HCL Market Size and Forecast, by Type

        11.3.1. Branded

        11.3.2. Generic

    11.4. North America Gemcitabine HCL Market Size and Forecast, by Application

        11.4.1. Pancreatic Cancer

        11.4.2. Breast Cancer

        11.4.3. Ovarian Cancer

        11.4.4. Non-small-cell lung carcinoma (NSCLC)

        11.4.5. Other

    11.5. North America Gemcitabine HCL Market Size and Forecast, by End-user

        11.5.1. Hospitals

        11.5.2. Cancer Centers 

        11.5.3. Others

    11.6. North America Gemcitabine HCL Market Forecast, by Country

        11.6.1. U.S.

        11.6.2. Canada

    11.7. North America Gemcitabine HCL Market Attractiveness Analysis 

        11.7.1. By Type

        11.7.2. By Application

        11.7.3. By End-user

        11.7.4. By Country

12. Europe Gemcitabine HCL Market Analysis

    12.1. Europe Gemcitabine HCL Market Key Findings

    12.2. Europe Gemcitabine HCL Market Overview

    12.3. Europe Gemcitabine HCL Market Size and Forecast, by Type

        12.3.1. Branded

        12.3.2. Generic

    12.4. Europe Gemcitabine HCL Market Size and Forecast, by Application

        12.4.1. Pancreatic Cancer

        12.4.2. Breast Cancer

        12.4.3. Ovarian Cancer

        12.4.4. Non-small-cell lung carcinoma (NSCLC)

        12.4.5. Other

    12.5. Europe Gemcitabine HCL Market Size and Forecast, by End-user

        12.5.1. Hospitals

        12.5.2. Cancer Centers 

        12.5.3. Others

    12.6. Europe Gemcitabine HCL Market Forecast, by Country

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy

        12.6.6. Rest of Europe

    12.7. Europe Gemcitabine HCL Market Attractiveness Analysis

        12.7.1. By Type

        12.7.2. By Application

        12.7.3. By End-user

        12.7.4. By Country

13. Asia Pacific Gemcitabine HCL Market Analysis

    13.1. Asia Pacific Gemcitabine HCL Market Key Findings

    13.2. Asia Pacific Gemcitabine HCL Market Overview

    13.3. Asia Pacific Cytometry Market Size and Forecast, by Type

        13.3.1. Branded

        13.3.2. Generic

    13.4. Asia Pacific Gemcitabine HCL Market Size and Forecast, by Application

        13.4.1. Pancreatic Cancer

        13.4.2. Breast Cancer

        13.4.3. Ovarian Cancer

        13.4.4. Non-small-cell lung carcinoma (NSCLC)

        13.4.5. Other

    13.5. Asia Pacific Gemcitabine HCL Market Size and Forecast, by End-user

        13.5.1. Hospitals

        13.5.2. Cancer Centers 

        13.5.3. Others

    13.6. Asia Pacific Gemcitabine HCL Market Forecast, by Country

        13.6.1. China

        13.6.2. India

        13.6.3. Japan

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Asia Pacific Gemcitabine HCL Market Attractiveness Analysis 

        13.7.1. By Type

        13.7.2. By Application

        13.7.3. By End-user

        13.7.4. By Country

14. Latin America Gemcitabine HCL Market Analysis

    14.1. Latin America Gemcitabine HCL Market Key Findings

    14.2. Latin America Gemcitabine HCL Market Overview

    14.3. Latin America Cytometry Market Size and Forecast, by Type

        14.3.1. Branded

        14.3.2. Generic

    14.4. Latin America Gemcitabine HCL Market Size and Forecast, by Application

        14.4.1. Pancreatic Cancer

        14.4.2. Breast Cancer

        14.4.3. Ovarian Cancer

        14.4.4. Non-small-cell lung carcinoma (NSCLC)

        14.4.5. Other

    14.5. Latin America Gemcitabine HCL Market Size and Forecast, by End-user

        14.5.1. Hospitals

        14.5.2. Cancer Centers 

        14.5.3. Others

    14.6. Latin America Gemcitabine HCL Market Forecast, by Country

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Latin America Gemcitabine HCL Market Attractiveness Analysis

        14.7.1. By Type

        14.7.2. By Application

        14.7.3. By End-user

        14.7.4. By Country

15. Middle East & Africa Gemcitabine HCL Market Analysis

    15.1. Middle East & Africa Gemcitabine HCL Market Key Findings

    15.2. Middle East & Africa Gemcitabine HCL Market Overview

    15.3. Middle East & Africa Cytometry Market Size and Forecast, by Type

        15.3.1. Branded

        15.3.2. Generic

    15.4. Middle East & Africa Gemcitabine HCL Market Size and Forecast, by Application

        15.4.1. Pancreatic Cancer

        15.4.2. Breast Cancer

        15.4.3. Ovarian Cancer

        15.4.4. Non-small-cell lung carcinoma (NSCLC)

        15.4.5. Other

    15.5. Middle East & Africa Gemcitabine HCL Market Size and Forecast, by End-user

        15.5.1. Hospitals

        15.5.2. Cancer Centers 

        15.5.3. Others

    15.6. Middle East Gemcitabine HCL Market Forecast, by Country

        15.6.1. South Africa

        15.6.2. Saudi Arabia

        15.6.3. U.A.E.

        15.6.4. Rest of Middle East & Africa

    15.7. Middle East Gemcitabine HCL Market Attractiveness Analysis 

        15.7.1. By Type

        15.7.2. By Application

        15.7.3. By End-user

        15.7.4. By Country

16. Competition Landscape

    16.1. Global Gemcitabine HCL Market Share Analysis, by Company (2018)

    16.2. Company Profiles

        16.2.1. Eli Lilly and Company

            16.2.1.1. Overview (HQ, Employee Strength, Business Segments)

            16.2.1.2. Financials

            16.2.1.3. Recent Developments

            16.2.1.4. Strategy

        16.2.2. Teva Pharmaceutical Industries Ltd.

            16.2.2.1. Overview (HQ, Employee Strength, Business Segments)

            16.2.2.2. Financials

            16.2.2.3. Recent Developments

            16.2.2.4. Strategy

        16.2.3. Accord-UK Ltd

            16.2.3.1. Overview (HQ, Employee Strength, Business Segments)

            16.2.3.2. Financials

            16.2.3.3. Recent Developments

            16.2.3.4. Strategy

        16.2.4. Pfizer Inc

            16.2.4.1. Overview (HQ, Employee Strength, Business Segments)

            16.2.4.2. Financials

            16.2.4.3. Recent Developments

            16.2.4.4. Strategy

        16.2.5. Mylan N.V.

            16.2.5.1. Overview (HQ, Employee Strength, Business Segments)

            16.2.5.2. Financials

            16.2.5.3. Recent Developments

            16.2.5.4. Strategy

        16.2.6. Sun Pharmaceutical Industries Ltd

            16.2.6.1. Overview (HQ, Employee Strength, Business Segments)

            16.2.6.2. Financials

            16.2.6.3. Recent Developments

            16.2.6.4. Strategy

        16.2.7. Fresenius Kabi AG

            16.2.7.1. Overview (HQ, Employee Strength, Business Segments)

            16.2.7.2. Financials

            16.2.7.3. Recent Developments

            16.2.7.4. Strategy

        16.2.8. Dr. Reddy’s Laboratories Ltd.

            16.2.8.1. Overview (HQ, Employee Strength, Business Segments)

            16.2.8.2. Financials

            16.2.8.3. Recent Developments

            16.2.8.4. Strategy

        16.2.9. Ingenus Pharmaceuticals

            16.2.9.1. Overview (HQ, Employee Strength, Business Segments)

            16.2.9.2. Financials

            16.2.9.3. Recent Developments

            16.2.9.4. Strategy

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Gemcitabine HCl Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2027